Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. - Wikidata - wikimedia - TriplyDB

Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial.

Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial.

http://www.wikidata.org/entity/Q44529241

about

Duration of adjuvant chemotherapy for patients with non-metastatic colorectal cancer Clinical management of localized colon cancer with capecitabine Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 mont Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised co Use of adjuvant chemotherapy in stage C (III) rectal cancer: comparison of data from matched patients in a teaching hospital's clinico-pathological database.An individual patient data meta-analysis of adjuvant therapy with uracil-tegafur (UFT) in patients with curatively resected rectal cancer.Adjuvant Chemotherapy Using the FOLFOX Regimen in Colon Cancer.Adjuvant Chemotherapy for Stage II Colon Cancer: The Role of Molecular Markers in Choosing Therapy Safety analysis of two different regimens of uracil-tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial Exploiting novel molecular targets in gastrointestinal cancers.Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy.Combination therapy in high-risk stage II or stage III colon cancer: current practice and future prospects.T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy.Overexpression of the Promigratory and Prometastatic PTK7 Receptor Is Associated with an Adverse Clinical Outcome in Colorectal Cancer Effectiveness of Adjuvant Chemotherapy with 5-FU/Leucovorin and Prognosis in Stage II Colon Cancer.Low-dose capecitabine adjuvant chemotherapy in elderly stage II/III colorectal cancer patients (LC-ACEC): study protocol for a randomized controlled trial.Chemotherapy use in stage III colon cancer: a National Cancer Database analysis Adjuvant therapies for colorectal cancer.Current stage-specific chemotherapeutic options in colon cancer.Adjuvant chemotherapy for colon cancer: a consensus statement of the Hellenic and Cypriot Colorectal Cancer Study Group by the HeSMO.Advances in the adjuvant treatment of colorectal cancer.CRC-113 gene expression signature for predicting prognosis in patients with colorectal cancer.Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients.Adjuvant sequential methotrexate --> 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer.A review of the role of capecitabine in the treatment of colorectal cancer.Adjuvant chemotherapy for colon cancer: evidence on improvement in survival.Chemotherapy for colorectal cancer in the metastatic and adjuvant setting: past, present and future.Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials.Status of targeted therapies in the adjuvant treatment of colon cancer Thromboembolism in gastrointestinal cancers.Current status of adjuvant therapy for colon cancer.Progress and challenges in the adjuvant treatment of stage II and III colon cancers.Update on targeted agents for adjuvant treatment of colon cancer in 2006.Adjuvant FOLFOX treatment for stage III colon cancer: how many cycles are enough?Outpatient-basis chemotherapy of oxaliplatin, 5-fluorouracil, and leucovorin as first-line treatment for patients with metastatic or recurrent colorectal cancer.Comparative efficacy of 5flourouracil/calcium leucovorine versus 5flourouracil/calcium leucovorine plus oxaliplatin in the adjuvant treatment of colonic carcinoma in Kashmir.Biotherapy in the Adjuvant Treatment of Colorectal Cancer Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.The role of bevacizumab in colorectal cancer: understanding its benefits and limitations.

P2860

Q24240635-172B5041-032E-416C-BBC0-8462F9890CAB Q24611758-9FDD2A42-A725-4748-9CAC-DAA190296D8E Q24653016-93B4174F-54C3-4DD9-844A-EED1726BF41F Q28681140-DA43DD39-AC9F-40B0-AA9E-F113EE00A92C Q30316930-190D17D0-13FC-494D-B888-C37B9B2B4962 Q30557842-0C16CF71-14F0-40E4-964F-53BCA20FB1DB Q31106341-8645773A-B75B-45C4-B3DF-412F56303908 Q33396630-E699BFA2-C524-4A44-9B39-6DFD2DD8DBD3 Q33591943-8E4C686A-4AA8-4E5F-ACDB-20A3D8F52C4A Q33656724-313C4C36-266B-453A-892A-ACC7DAFE2B35 Q34382777-D3E53261-BB90-4C21-98B7-A3A79008CFED Q34632080-2AB796D9-101D-4266-B114-4D3CA353C938 Q35076279-8DC6774E-122A-40FA-B074-DCA641FA7F45 Q35108491-7B80522C-4B53-4EB6-96E2-387AFB4993A7 Q35593473-24D1E234-C775-42EB-8C28-45053328C936 Q35675831-2241D550-4FFB-4884-A209-8D54BC97727D Q35733020-66562E8B-D8F0-49A9-BF4E-FCD4A408EA57 Q35978879-BBD581D7-3B20-425B-B786-1EFB0AA01691 Q36177963-494C5029-3FC0-4D0F-86CE-F7B87AA17CE0 Q36235576-98BE2C88-3DB2-4AE8-9BA1-F6D57271228B Q36429095-9786A4FE-EED1-4B70-A457-6228F4BFD521 Q36503798-41183631-5836-4705-8155-8D140F2CA5B8 Q36544662-4CDF2694-4D9D-4417-B8D9-8C1760F63EF6 Q36609950-7F8C09C1-D742-4884-96F5-1AAE3802C265 Q36615696-DDDB15D1-3D5D-4417-AC47-453DC9C24EBA Q36661290-23013FA2-52BE-4977-A069-77BEF93CA58E Q36769806-F435D88E-5751-4023-8369-35BEF898B3E8 Q36788478-60009C80-07D4-4509-A827-AF57FA650F31 Q36862977-05E846A0-C65F-4CFF-87B3-E2CD4CFE6D43 Q37015712-D28C71D5-2CCD-49BD-B647-05F87DC46E3F Q37076622-E8E9CB11-1785-43C8-931B-4A80AE643F87 Q37077225-A6C6834F-DBBF-4E36-91AB-F5D0A612DDF8 Q37134442-5DDA097A-D833-4EA5-9657-5459DEF68DCA Q37153311-AA7BDDA5-BBAD-4B1A-B3C1-53F5BF49DB1C Q37167151-17E72A00-F35A-401D-BFEC-34CDD5147DCD Q37220492-A3D2130D-3192-4ADA-9807-FD6598117AB5 Q37422332-D6A7EC90-7BD6-42EB-8AB4-EB6A04F4FB3C Q37477466-1D94AE02-E5CB-4797-A21B-126DEA0B46DC Q37697523-72A47718-0E31-45C0-8271-C1B480797FAE Q37833645-A1D0F7BE-4A50-45D5-AB33-43C85B0308E0

P2860

Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial.

http://www.wikidata.org/entity/Q44529241

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Semimonthly versus monthly reg ...... results of a randomized trial.

@en

Semimonthly versus monthly reg ...... results of a randomized trial.

@nl

type

label

Semimonthly versus monthly reg ...... results of a randomized trial.

@en

Semimonthly versus monthly reg ...... results of a randomized trial.

@nl

prefLabel

Semimonthly versus monthly reg ...... results of a randomized trial.

@en

Semimonthly versus monthly reg ...... results of a randomized trial.

@nl

P1433

Q44529241-CC742E04-9A12-453A-B3F0-F8460F074D95

P1476

Q44529241-964026A6-3B2C-4D91-9A36-2492527900F1

P2093

Q44529241-0CEDACE9-31C1-4925-A486-3F858CC8F978

Q44529241-1907EDE1-3C07-44AF-AD08-E1955088F494

Q44529241-1D4A6EB3-8DAD-4FD2-9E56-5720FA8FC1A1

Q44529241-266E264D-49AA-4098-BD8A-129FB4B487F4

Q44529241-332BFC70-CEDB-4F08-91D7-624DF3D45DE1

Q44529241-431D85B5-D52F-4E6A-B0D1-C9613EF6D2EE

Q44529241-45704561-9068-4F85-B0DD-F0DD9C905AB9

Q44529241-46750416-A9FC-441A-B1BD-BBF076771540

Q44529241-5230E4BA-E6B6-46E2-9BE0-F79069D88192

Q44529241-57B2D7BA-FE10-41F2-8416-CAB01DDCF32F

P304

Q44529241-B72048A5-BAD9-4313-A499-56AAE6A50B73

P31

Q44529241-01FE6A01-8CB9-444B-B58D-608B06C769A3

P356

Q44529241-0CBA9DF1-613D-4A6C-91A2-F2B2F80737DD

P407

Q44529241-1063F0D7-A50B-4F91-AE79-E4D061170C0B

P433

Q44529241-D67F9096-580B-4B29-B332-AB31B5AEAC8C

P478

Q44529241-534CA979-6177-4754-AEE0-59E133D0EC26

P50

Q44529241-7DF55942-9BC4-49CE-AECB-551538A9D935

Q44529241-8748C121-E088-4BFA-BBAB-997F3B5C3B37

P577

Q44529241-424CA16B-9786-4FBB-9B10-571C9649D211

P698

Q44529241-4D47C161-AE4C-4FE3-944A-5B3610EAB186

P356

JCO.2003.10.065

P1433

Journal of Clinical Oncology

P1476

Semimonthly versus monthly reg ...... results of a randomized trial

@en

P2093

Aimery de Gramont

http://www.w3.org/2001/XMLSchema#string

Arnaud Boutan-Laroze

http://www.w3.org/2001/XMLSchema#string

Catherine Boaziz

http://www.w3.org/2001/XMLSchema#string

Christophe Louvet

http://www.w3.org/2001/XMLSchema#string

Emmanuel Achille

http://www.w3.org/2001/XMLSchema#string

Erik Gamelin

http://www.w3.org/2001/XMLSchema#string

Marc Buyse

http://www.w3.org/2001/XMLSchema#string

Michel Flesch

http://www.w3.org/2001/XMLSchema#string

Nicolas Colbert

http://www.w3.org/2001/XMLSchema#string

Olivier Bouche

http://www.w3.org/2001/XMLSchema#string

P304

2896-2903

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2003.10.065

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Nicole Tubiana Mathieu

P577

2003-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12885807

http://www.w3.org/2001/XMLSchema#string